These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33617871)

  • 1. An Industry Perspective on the Challenges of Using Closed System Transfer Devices with Biologics and Communication Guidance to Healthcare Professionals.
    Gopalrathnam G; Christian TR; Jagannathan B; Petoskey F; Kühnle B; Weiser S; Kagdi R; Saluja S; Bhattacharyya A; Burton L; Zamiri C; Hanley K
    J Pharm Sci; 2021 Jun; 110(6):2329-2335. PubMed ID: 33617871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges of Using Closed System Transfer Devices With Biological Drug Products: An Industry Perspective.
    Sreedhara A; Zamiri C; Goswami S; Weiser S; Cram M; Christian TR; Jagannathan B
    J Pharm Sci; 2020 Jan; 109(1):22-29. PubMed ID: 31697946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Closed-system transfer device use with oncology biologics: A survey of Canadian healthcare practitioners.
    Khaira M; Guy AL
    J Oncol Pharm Pract; 2022 Jun; 28(4):805-815. PubMed ID: 34000919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Industry Perspective on Compatibility Assessment of Closed System Drug-Transfer Devices for Biologics.
    Besheer A; Burton L; Galas RJ; Gokhale K; Goldbach P; Hu Q; Mathews L; Muthurania K; Narasimhan C; Singh SN; Stokes ESE; Weiser S; Zamiri C; Zhou S
    J Pharm Sci; 2021 Feb; 110(2):610-614. PubMed ID: 33127425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Different Quality-Relevant Aspects of Closed System Transfer Devices (CSTDs).
    Besheer A; Mahler HC; Matter-Schwald A; Barrenechea SM; Vogt M; Chalus P; Heymes P; Pillow T; Kirste A; Favrod P; Joerg S; Mathaes R
    Pharm Res; 2020 Apr; 37(4):81. PubMed ID: 32274594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of unintended volume loss of six closed system transfer devices.
    Kulju S; McIntosh BA; Fuller HJ; Arnold T; Gunnar W
    J Oncol Pharm Pract; 2020 Jul; 26(5):1134-1140. PubMed ID: 31775580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance testing protocol for closed-system transfer devices used during pharmacy compounding and administration of hazardous drugs.
    Wilkinson AS; Allwood MC; Morris CP; Wallace A; Finnis R; Kaminska E; Stonkute D; Szramowska M; Miller J; Pengelly I; Hemingway M
    PLoS One; 2018; 13(10):e0205263. PubMed ID: 30379831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Approach to Evaluating Closed System Drug-Transfer Devices During Drug Product Development.
    Patke S; Gaillat EN; Calero-Rubio C; Gooding TB; Audat H; Leman M; Filipe V; Saluja A
    J Pharm Sci; 2022 May; 111(5):1325-1334. PubMed ID: 34958824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishing a protocol for the compatibilities of closed-system transfer devices with multiple chemotherapy drugs under simulated clinical conditions.
    Chiang SC; Shen M; Lin CC; Chang HP
    PLoS One; 2021; 16(9):e0257873. PubMed ID: 34582474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs).
    Sumikawa S; Yakushijin Y; Aogi K; Yano T; Hiroki ; Hashimoto ; Tsukui C; Noguchi T; Shiraishi T; Horikawa Y; Yasuoka Y; Tanaka A; Hidaka N; Tanaka M
    Sci Rep; 2022 Jan; 12(1):139. PubMed ID: 34996936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Case Study to Address a Gap in the Device-to-Vial Interface Stopper Push-in by Chemo Spikes.
    Zhao XC; Ho L; Bantz D; Hostetler D; Fang L
    PDA J Pharm Sci Technol; 2019; 73(1):92-109. PubMed ID: 30232140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of Holdup Volume and Transient Contact Compatibility of Closed System Transfer Devices for a Reconstituted Lyophilized Drug Product.
    Kagdi R; Le K; Doucet D; Ludlow J; Rinella JV
    J Pharm Sci; 2020 Nov; 109(11):3504-3511. PubMed ID: 32771346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming Challenges of Implementing Closed System Transfer Device Clinical In-Use Compatibility Testing for Drug Development of Antibody Drug Conjugates.
    Petoskey F; Kwok SC; Jackson W; Jiang S
    J Pharm Sci; 2020 Jan; 109(1):761-768. PubMed ID: 31376374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating Six Commercially Available Closed-System Drug-Transfer Devices Against NIOSH's 2015 Draft Vapor Protocol.
    Halloush S; Reveles IA; Koeller J
    Hosp Pharm; 2020 Dec; 55(6):391-399. PubMed ID: 33245720
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of three barrier-type closed system transfer devices using the 2015 NIOSH vapor containment performance draft protocol.
    Szkiladz A; Hegner S
    Drugs Ther Perspect; 2022; 38(4):177-184. PubMed ID: 35313703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Container closure integrity testing and process validation of closed system transfer devices for aseptic reconstitution of drug vials connected to fluid bags.
    van den Berg RB; Akgöl K; Swart EL; Nuijen B; Crul M
    Eur J Hosp Pharm; 2024 Jun; 31(4):358-362. PubMed ID: 36792349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and reduction of hazardous drug surface contamination through the use of a novel closed-system transfer device coupled with a point-of-care hazardous drug detection system.
    Brechtelsbauer E
    Am J Health Syst Pharm; 2023 Mar; 80(7):435-444. PubMed ID: 36370411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Closed System Transfer Devices (CSTDs): Understanding Potential Over- and Under- Dosing of Liquid Vial Drug Products and How to Generally Mitigate.
    Lehermayr C; Schmelzer B; Kropf M
    J Pharm Sci; 2023 Sep; 112(9):2532-2537. PubMed ID: 37146755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a simple compatibility inspection method using pressure in a BD PhaSeal™ system and hazardous drug vials.
    Ishimaru H; Tsuda Y; Kage H; Kawano T; Takayama S; Morimoto Y; Goto K; Watanabe K
    J Oncol Pharm Pract; 2021 Sep; 27(6):1321-1327. PubMed ID: 32854576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.